Attached files

file filename
EX-99.1 - PRESS RELEASE - Avid Bioservices, Inc.peregrine_8k-ex9901.htm



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC  20549
 

FORM 8-K
 

CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 24, 2011
 

PEREGRINE PHARMACEUTICALS, INC. 
(Exact name of registrant as specified in its charter)
 
Delaware
 
0-17085
 
95-3698422
(State of other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
         
14282 Franklin Avenue, Tustin, California 92780
(Address of Principal Executive Offices)
         
Registrant’s telephone number, including area code: (714) 508-6000
 
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
  o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  o            Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
  o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
  o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



 
 

 

Item 8.01     Other Events.

On August 24, 2011, Peregrine Pharmaceuticals, Inc. issued a press release announcing clinical data results from a Phase II trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer.

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.


Item 9.01     Financial Statements and Exhibits.
 
 
(d)           Exhibits.  The following material is filed as an exhibit to this Current Report on Form 8-K:

Exhibit
Number
 
99.1           Press Release issued August 24, 2011.
 
 
 
 
 
 
 

 

 
2

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
PEREGRINE PHARMACEUTICALS, INC.
   
   
   
Date: August 24, 2011
By:  /s/ Paul J. Lytle
 
Paul J. Lytle
 
Chief Financial Officer
 
 
 
 
 
 
 

 
 
3

 


 
 
EXHIBIT INDEX
 
 
Exhibit
 
Number
Description
   
99.1
Press Release issued August 24, 2011